Chlamydia pneumoniae
Chlamydia pneumoniae | |
---|---|
Scientific classification | |
Domain: | Bacteria |
Phylum: | Chlamydiota |
Class: | Chlamydiia |
Order: | Chlamydiales |
Family: | Chlamydiaceae |
Genus: | Chlamydia |
Species: | C. pneumoniae
|
Binomial name | |
Chlamydia pneumoniae Grayston et al. 1989
| |
Synonyms | |
|
Chlamydia pneumoniae
Chlamydia pneumoniae has a complex life cycle and must infect another cell to
The first known case of infection with C. pneumoniae was a case of conjunctivitis in Taiwan in 1950. There are no known cases of C. pneumoniae in human history before 1950. This atypical bacterium commonly causes pharyngitis, bronchitis, coronary artery disease and atypical pneumonia in addition to several other possible diseases.[7][8]
Life cycle and method of infection
Chlamydia pneumoniae is a small gram-negative bacterium (0.2 to 1
Diseases
Chlamydia pneumoniae is a common cause of pneumonia around the world; it is typically acquired by otherwise-healthy people and is a form of community-acquired pneumonia. Its treatment and diagnosis are different from historically recognized causes, such as Streptococcus pneumoniae.[10] Because it does not gram stain well, and because C. pneumoniae bacteria is very different from the many other bacteria causing pneumonia (in the earlier days, it was even thought to be a virus), the pneumonia caused by C. pneumoniae is categorized as an "atypical pneumonia".[11]
One
In research into the association between C. pneumoniae infection and
Chlamydia pneumoniae has also been found in the cerebrospinal fluid of patients diagnosed with multiple sclerosis.[18]
Chlamydia pneumoniae infection was first associated with wheezing, asthmatic bronchitis, and adult-onset asthma in 1991.[19] Subsequent studies of bronchoalveolar lavage fluid from pediatric patients with asthma and also other severe chronic respiratory illnesses have demonstrated that over 50 percent had evidence of C. pneumoniae by direct organism identification.[20][21] C. pneumoniae infection triggers acute wheezing, if it becomes chronic then it is diagnosed as asthma.[22] These observations suggest that acute C. pneumoniae infection is capable of causing protean manifestations of chronic respiratory illness which lead to asthma.[23]
Macrolide antibiotic treatment can improve asthma in a subgroup of patients that remains to be clearly defined. Macrolide benefits were first suggested in two observational trials[24][25] and two randomized controlled trials[26][27] of azithromycin treatment for asthma. One of these RCTs[27] and another macrolide trial[28] suggest that the treatment effect may be greatest in patients with severe, refractory asthma. These clinical results correlate with epidemiological evidence that C. pneumoniae is positively associated with asthma severity[29] and laboratory evidence that C. pneumoniae infection creates steroid-resistance.[30] A meta analysis of 12 RCTs of macrolides for the long term management of asthma found significant effects on asthma symptoms, quality of life, bronchial hyper reactivity and peak flow but not FEV1.[31] More recent positive results of long-term treatment with azithromycin on asthma exacerbations and quality-of-life in patients with severe, refractory asthma[32][33] have resulted in azithromycin now being recommended in international guidelines as a treatment option for these types of patients.[34]
A recent case series of 101 adults with asthma reported that macrolides (mostly azithromycin) and tetracyclines, either separately or in combination, appeared to be dramatically efficacious in a subgroup of "difficult-to-treat" (i.e., not necessarily refractory to high-dose inhaled corticosteroids but who did not take them) patients with severe asthma, many of whom also had the "overlap syndrome" (asthma and COPD).[35] Randomized, controlled trials that include these types of asthma patients are needed.
Chlamydia pneumoniae infection is also associated with schizophrenia. Many other pathogens have been associated with schizophrenia.[36]
Vaccine research
There is currently no vaccine to protect against Chlamydia pneumoniae. Identification of immunogenic antigens is critical for the construction of an efficacious subunit vaccine against C. pneumoniae infections. Additionally, there is a general shortage worldwide of facilities that can identify/diagnose Chlamydia pneumoniae.[citation needed]
References
- PMID 10319462.
- ^ Chlamydia+pneumoniae at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- ^ Mayer G (24 June 2010). "Bacteriology - Chapter Twenty: Chlamydia and Chlamydophila". Bacteriology Section of Microbiology and Immunology On-line. University of South Carolina School of Medicine. Archived from the original on 2014-11-11.
- ^ "Chlamydia pneumoniae". Taxonomy Browser. National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Retrieved 2009-01-27.
- PMID 18218130.
- S2CID 24629065.
- ^ Lang BR (September 15, 1991). "Chlamydia pneumonia as a differential diagnosis? Follow-up to a case report on progressive pneumonitis in an adolescent". Patient Care.
- ^ Little L (September 19, 1991). "Elusive pneumonia strain frustrates many clinicians". Medical Tribune: 6.
- ^ "Chlamydial Infections". The Lecturio Medical Concept Library. Retrieved 8 July 2021.
- PMID 19623657.
- PMID 16669925.
- PMID 21194924.
- PMID 16566840.
- S2CID 6510957.
- S2CID 6103162.
- PMID 18070891.
- PMID 16765261.
- S2CID 29779286.
- PMID 2056624.
- S2CID 43107174.
- PMID 15735056.
- PMID 9809498.
- PMID 28526018.
- PMID 7561707.
- PMID 22545149.
- PMID 16871333.
- ^ PMID 22773713.
- PMID 17947611.
- S2CID 21900343.
- S2CID 84290541.
- S2CID 17057866.
- S2CID 4523731.
- PMID 31886156.
- ^ GINA. "Difficult-to-Treat and Severe Asthma in Adolescent and Adult Patients: Diagnosis and Management". Global Initiative for Asthma. Retrieved August 1, 2021.
- PMID 34163182.
- S2CID 2687441.